OUP user menu

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy

M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, D.J. Moliterno, C. Heeschen, C.W. Hamm, M.A. Robbins, N.S. Kleiman, P. Théroux, H.D. White, E.J. Topol
DOI: http://dx.doi.org/10.1053/euhj.2002.3160 1441-1448 First published online: 2 September 2002


Aims To assess the efficacy of platelet glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed.

Methods and Results We performed a meta-analysis of the randomized clinical trials of platelet glycoprotein IIb/IIIa inhibitor therapy in the medical management of non-ST-elevation acute coronary syndromes. Among 29570 patients, IIb/IIIa integrin blockade was associated with a reduction in death or non-fatal myocardial infarction at 30 days, from 11·5% to 10·7% (odds ratio 0·91,P =0·02). Patients undergoing percutaneous coronary intervention during index hospitalization sustained a greater reduction in ischaemic events (odds ratio 0·82, P=0·01) than patients medically managed (odds ratio 0·95, P=0·27). Among patients undergoing intervention, the benefit was more pronounced if the procedure was performed during glycoprotein IIb/IIIa inhibitor infusion (odds ratio 0·74; P=0·02), than if revascularization was performed after drug discontinuation (odds ratio 0·87,P =0·17).

Conclusion This analysis, including the entire large-scale trial experience of intravenous glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes primarily medically managed, demonstrates an overall significant, albeit moderate, reduction in 30-day death or myocardial infarction associated with therapy. Although not based on a prospectively defined hypothesis, the findings suggest a gradient of benefit conferred by these agents depending on the revascularization strategy used. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

  • Acute coronary syndromes, abciximab, eptifibatide, lamifiban, tirofiban, glycoprotein IIb/IIIa receptor inhibitors